FDA approves citrate-free, high-concentration form of biosimilar Hyrimoz

The FDA has approved a citrate-free, high-concentration formulation of the adalimumab biosimilar Hyrimoz, according to a press release from the manufacturer.The 100 mg/mL formulation of Hyrimoz (adalimumab-adaz, Novartis Sandoz) is expected to launch in the U.S. marketplace on July 1, Sandoz stated.“As one of the first adalimumab high-concentration formulation biosimilars approved in the U.S., Hyrimoz [high-concentration formulation (HCF)] has the potential to expand access for millions of people who face the realities of living with a serious inflammatory disease and to enhance theRead More